早期SSTR靶向PRRT在胃肠胰神经内分泌肿瘤中是否有角色?
该系统性综述依据PRISMA指南检索PubMed与clinicaltrials.gov至2025年5月31日,纳入25篇评估新辅助、辅助或一线PRRT在GEP-NET中应用的文献。初步数据显示新辅助PRRT可使最多45%患者从不可切除转为可切除,客观缓解率高达70%,NETTER-2试验支持[¹⁷⁷Lu]Lu-DOTATATE一线治疗SSTR阳性G2-G3 GEP-NET并显著改善无进展生存期,但辅助治疗证据缺失。
要点
- 新辅助PRRT可使最多45%的GEP-NET患者从不可切除转为可切除。
- 新辅助PRRT报告的客观缓解率高达70%,并可能改善手术可行性与生存。
- NETTER-2初步结果支持[¹⁷⁷Lu]Lu-DOTATATE一线用于SSTR阳性G2-G3 GEP-NET。
核心结论
- 当前数据提示PRRT传统上作为后线治疗获批,但在经选择的GEP-NET患者中可能在新辅助和一线设置中发挥有前景的作用。
研究设计与样本
- 系统综述按照PRISMA指南进行,纳入评估GEP-NET中新辅助、辅助或一线PRRT的病例报告、原创论文和临床试验方案。
- 系统检索PubMed和clinicaltrials.gov(截至2025年5月31日),最终确定25篇符合条件的论文。
主要发现
- 现有初步数据包括病例报告、回顾性和前瞻性队列,显示新辅助PRRT可诱导肿瘤缩小、血管受累消退以及从不可切除转为可切除,最高达45%的患者。
- 报告结局包括高客观缓解率(高达70%)、手术可行性改善以及有希望的生存获益,尤其在术前接受PRRT的患者中。
- NETTER-2试验的初步结果支持[¹⁷⁷Lu]Lu-DOTATATE作为SSTR阳性G2-G3 GEP-NET的一线治疗,显示无进展生存期显著改善。
- 辅助使用的证据缺失。
关键数值与推荐
- 新辅助PRRT可使最多45%的患者从不可切除转为可切除。
- 新辅助PRRT报告的客观缓解率高达70%。
- NETTER-2试验初步结果支持[¹⁷⁷Lu]Lu-DOTATATE一线治疗SSTR阳性G2-G3 GEP-NET,显示无进展生存期显著改善。
临床怎么用
- 对于经选择的GEP-NET患者,可考虑在新辅助或一线设置中应用PRRT以增强可切除性、改善手术结局并可能延长生存。
局限性
- 需要进一步的前瞻性随机研究来确定选择标准、确定最佳时机并评估对疾病轨迹的长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues, such as [¹⁷⁷Lu]Lu-DOTATATE, is approved as a second-line treatment for progressive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, emerging evidence suggests potential earlier roles for PRRT. MATERIALS AND METHODS: A systematic review was conducted in accordance with the PRISMA guidelines, including case reports, original papers, and clinical trial protocols evaluating neoadjuvant, adjuvant, or first-line PRRT in GEP-NETs. A systematic search of PubMed and clinicaltrials.gov (up to May 31, 2025) finally identified 25 eligible papers. For each paper, data were extracted regarding clinical setting, patient characteristics, treatment regimen, and oncologic and surgical outcomes. RESULTS: The available preliminary data, comprising case reports, retrospective and prospective cohorts, show that neoadjuvant PRRT can induce tumor shrinkage, regression of vascular involvement, and conversion from unresectable to resectable disease in up to 45% of patients. Reported outcomes include high objective response rates (up to 70%), improved surgical feasibility, and a promising survival benefit, especially in patients who received PRRT before surgery. Also, preliminary results from the NETTER-2 trial support the use of [¹⁷⁷Lu]Lu-DOTATATE as first-line therapy in SSTR-positive G2-G3 GEP-NET, showing significant improvement in progression-free survival. Differently, the evidence for adjuvant use is missing. CONCLUSION: Current data suggest that PRRT, traditionally approved as a later-line therapy, may play a promising role in neoadjuvant and first-line settings for selected GEP-NET patients, enhancing resectability, improving surgical outcomes, and potentially prolonging survival. Further prospective, randomized studies are needed to define selection criteria, determine optimal timing, and assess the long-term impact on disease trajectory.
引用
- Ricciardello G, Celesti G, Bauckneht M, et al. Is there a role for early SSTR-targeting PRRT in GEP-NET? Eur J Nucl Med Mol Imaging. 2026. PMID: 42234009. doi:10.1007/s00259-026-07974-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。